AbbVie 2026: Revenue $17.4B, Net income $4.22B, EPS $2.37— 10-Q Summary

What happened

AbbVie reported 2026-period net revenues of $17.4B and net income of $4.22B, compared with $15.78B and $186M in the prior-year period. Diluted earnings per share, or profit allocated to each share, was $2.37, up from $0.1. The article also describes growth in newer medicines and U.S. investment plans.

Confirmed

Global impact / market context

Higher revenue and earnings can support AbbVie’s capacity to fund research and manufacturing, while growth in Skyrizi and Rinvoq may help offset Humira’s biosimilar-driven decline. If newer medicines sustain demand, they could contribute more sales; if not, pressure from older-product competition may remain.

Analyst inference

The article presents a business mix in transition: Skyrizi and Rinvoq are growing while Humira faces biosimilar competition, and several other medicines also recorded growth. The announced U.S. investment pledge and expected drug-development milestones could shape future spending and sales, but outcomes are not guaranteed.

Analyst inference

What to watch

1. Track whether Skyrizi and Rinvoq continue growing enough to offset Humira’s decline, since that balance directly affects AbbVie’s sales mix and future revenue. Analyst inference
2. Watch for the expected drug submissions, approvals, and trial results over the next 12 months; these could determine when development advances translate into sales. Confirmed
3. Follow details and execution of the announced U.S. manufacturing investments and 10-year, $100B research, development, and capital investment pledge under the government access agreement. Confirmed

Evidence

• Original source link unavailable